Format

Send to

Choose Destination
Circ Res. 2015 Jul 17;117(3):229-33. doi: 10.1161/CIRCRESAHA.117.306306.

Mesenchymal Stem Cells as a Biological Drug for Heart Disease: Where Are We With Cardiac Cell-Based Therapy?

Author information

1
From the Interdisciplinary Stem Cell Institute (C.S., J.M.H.), Department of Medicine, Division of Cardiology (J.M.H.), and Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, FL (J.M.H.).
2
From the Interdisciplinary Stem Cell Institute (C.S., J.M.H.), Department of Medicine, Division of Cardiology (J.M.H.), and Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, FL (J.M.H.). jhare@med.miami.edu.

Abstract

Cell-based treatment represents a new generation in the evolution of biological therapeutics. A prototypic cell-based therapy, the mesenchymal stem cell, has successfully entered phase III pivotal trials for heart failure, signifying adequate enabling safety and efficacy data from phase I and II trials. Successful phase III trials can lead to approval of a new biological therapy for regenerative medicine.

KEYWORDS:

cell- and tissue-based therapy; chronic heart failure; clinical trial; heart disease; mesenchymal stem cells

PMID:
26185208
PMCID:
PMC4571454
DOI:
10.1161/CIRCRESAHA.117.306306
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center